Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTR2B | P41595 | 4/20 | 0.39 |
| ▸ | CDK1 | P06493 | 8/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.37 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30124448 | 0.78 | SMN1; SMN2 (0.48) | TSHRNPC1RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL9635086 | 0.76 | BRD4 (0.45) | TSHRPARP3CA12CA9L3MBTL1 | |
| SCHEMBL9635252 | 0.76 | TSHR (0.53) | TSHRNPC1SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL23863601 | 0.71 | — | — | |
| SCHEMBL13939432 | 0.70 | CA12 (0.63) | CA12CA9L3MBTL1ALDH1A1 | |
| SCHEMBL14259805 | 0.69 | L3MBTL1 (0.48) | TSHRNPC1RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL1708834 | 0.69 | TSHR (0.44) | TSHRSMN1; SMN2PARP3L3MBTL1ALDH1A1 | |
| SCHEMBL9635192 | 0.69 | CA12 (0.39) | TSHRHTR2AHTR2CHTR2BPARP3 | |
| SCHEMBL6200350 | 0.69 | TSHR (0.45) | TSHRNPC1RAB9ACYP1A2SMN1; SMN2 | |
| SCHEMBL8658609 | 0.69 | CA12 (0.45) | TSHRCA12CA9L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | TSHR 3779/4885NPC1 3437/4885RAB9A 3101/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | TSHR 3779/4885NPC1 3437/4885RAB9A 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.